Experts discuss triple-negative breast cancer
From OncLive, five experts share their perspectives and opinions on the latest research related to triple-negative breast cancer.
Participants include Joyce A. O'Shaughnessy, MD, Baylor-Sammons Cancer Center; Adam M. Brufsky, MD, University of Pittsburg Cancer Institute; Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center; Kevin M. Kalinsky, MD, Columbia University Medical Center; and Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute.
The experts discuss new data from the European Society for Medical Oncology’s (ESMO) Virtual Congress 2020 and standards of care for early-stage triple-negative breast cancer.
“I think that increasingly for our patients with early-stage triple-negative breast cancer, we treat with neoadjuvant chemotherapy. I think that this is for a number of reasons so that we could see how patients are responding to the treatments that we’re giving,” said Dr. Kalinsky.
Visit OncLive to hear their perspectives.
Shift towards neoadjuvant chemotherapy found in ovarian cancer treatment
October 21st 2024A recent study shows a significant decrease in primary cytoreductive surgery utilization for advanced ovarian cancer, as neoadjuvant chemotherapy followed by interval cytoreductive surgery gains acceptance for its noninferior survival outcomes and reduced postoperative morbidity.
Read More
Family history criteria used to predict breast cancer genetic risk variants
September 26th 2024In a recent study, patients with a positive response to the Seven-Question Family History Questionnaire were more likely to present with a pathogenic or likely pathogenic variant in the BRCA1 and BRCA2 genes.
Read More
